Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction - 18/12/20
, John J.P. Kastelein, MD b, Adam T. Phillips, MD a, Philip E. Aylward, MD c, Megan K. Yee, MPH a, Michal Tendera, MD d, Stephen J. Nicholls, MD, PhD e, Stuart Pocock, PhD f, Shaun G. Goodman, MD, MSc g, John H. Alexander, MD, MHS h, A. Michael Lincoff, MD i, Christoph Bode, MD j, Danielle Duffy, MD k, Mark Heise, PhD k, Gail Berman, MD l, Sojaita Jenny Mears, MS k, Pierluigi Tricoci, MD, PhD, MHS h, k, 1, Lawrence I. Deckelbaum, MD k, P. Gabriel Steg, MD m, Paul Ridker, MD n, Roxana Mehran, MD oAbstract |
Acute myocardial infarction (MI) patients remain at high risk for recurrent events. Cholesterol efflux, mediated by apolipoprotein A-I, removes excess cholesterol from atherosclerotic plaque and transports it to the liver for excretion. Impaired cholesterol efflux is associated with higher cardiovascular (CV) event rates among both patients with stable coronary artery disease and recent MI. CSL112, a novel intravenous formulation of apolipoprotein A-I (human) derived from human plasma, increases cholesterol efflux capacity.
AEGIS-II is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial investigating the efficacy and safety of CSL112 compared to placebo among high-risk acute MI participants. Eligibility criteria include age ≥ 18 years with type 1 (spontaneous) MI, evidence of multivessel stable coronary artery disease, and presence of diabetes requiring pharmacotherapy, or ≥2 of the following: age ≥ 65 years, prior MI, or peripheral artery disease. A target sample of 17,400 participants will be randomized 1:1 to receive 4 weekly infusions of CSL112 6 g or placebo, initiated prior to or on the day of discharge and within 5 days of first medical contact. The primary outcome is the time to first occurrence of the composite of CV death, MI, or stroke through 90 days. Key secondary outcomes include the total number of hospitalizations for coronary, cerebral, or peripheral ischemia through 90 days and time to first occurrence of the composite primary outcome through 180 and 365 days.
AEGIS-II will be the first trial to formally test whether enhancing cholesterol efflux can reduce the rate of recurrent major adverse CV events.
Le texte complet de cet article est disponible en PDF.Plan
| All authors have received research grant support from the sponsor of the study. D. Duffy, M. Heise, G. Berman, S. J. Mears, P. Tricoci, and L. I. Deckelbaum are employees of CSL Behring. The authors are solely responsibly for the design and conduct of this study, all study analyses, the drafting and editing of the paper, and its final contents. All authors have materially participated in the manuscript preparation, provided critical contributions to the manuscript, and approved the final submitted version. |
Vol 231
P. 121-127 - janvier 2021 Retour au numéro
Article précédent
- Randomized evaluation of beta blocker and ACE-inhibitor/angiotensin receptor blocker treatment in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA-BAT): Rationale and design
- Anna M Nordenskjöld, Stefan Agewall, Dan Atar, Tomasz Baron, John Beltrame, Olle Bergström, David Erlinge, Chris P Gale, Javier López-Pais, Tomas Jernberg, Pelle Johansson, Annica Ravn-Fisher, Harmony R. Reynolds, Jithendra B. Somaratne, Per Tornvall, Bertil Lindahl
- A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial
- Helio P. Guimarães, Pedro G.M. de Barros e Silva, Idelzuita L. Liporace, Roney O. Sampaio, Flávio Tarasoutchi, Milena Paixão, Conrado R. Hoffmann-Filho, Rodrigo Patriota, Tiago L.L. Leiria, Diana Lamprea, Dalton B. Precoma, Fernando A. Atik, Fabio S. Silveira, Fabio R. Farias, Diogo O. Barreto, Adail P. Almeida, Alexandre C. Zilli, João D. de Souza Neto, Margaret A. Cavalcante, Fernando A.M.S. Figueira, Roque A. Junior, Valdir A. Moisés, Cezar E. Mesas, Roberto V. Ardito, Paulo S.A. Kalil, Maria S.M.O. Paiva, Jaime G.A. Maldonado, Carlos E.B. de Lima, Ricardo D'Oliveira Vieira, Ligia Laranjeira, Flávia Kojima, Lucas Damiani, Renato H. Nakagawa, Juliana R.Y. dos Santos, Bruna S. Sampaio, Viviane B. Campos, Jose F.K. Saraiva, Francisco H. Fonseca, Ibraim M. Pinto, Carlos C. Magalhães, Joao F.M. Ferreira, Renato D. Lopes, Ricardo Pavanello, Alexandre B. Cavalcanti, Otavio Berwanger, On behalf of the RIVER (RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER Trial) Investigators
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?